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Metastatic acral lentiginous melanoma in a tertiary referral
center in Switzerland: a systematic analysis
Esther M. Häfligera,b, Egle Ramelytea, Joanna Manganaa, Michael Kunza,
Dmitry V. Kazakova,c, Reinhard Dummera and Phil F. Chenga
Acral lentiginous melanoma (ALM) is a unique
histopathological subtype of melanoma with a poorer
prognosis than other cutaneous melanomas. This study
aims to evaluate the clinicopathological characteristics,
metastatic pattern, prognostic factors, response to systemic
therapy, and overall survival (OS) of ALM in a White
population. This is a retrospective study of patients who
were diagnosed and/or treated for ALM at the Department
of Dermatology of the University Hospital Zurich,
Switzerland, from January 2005 to December 2015. Overall,
172 patients with histologically confirmed ALM were
included in the study. In univariate Cox regression, Breslow
thickness (P< 0.001), age (P= 0.003), status of sentinel
lymph node (P= 0.005), and ulceration (P= 0.008) were
identified as significant prognostic factors for OS in ALM. In
multivariate analysis, only Breslow thickness (P= 0.0003)
showed statistical significance. The median OS (mOS) was
155.7 months in the entire cohort (n= 172) and 11.2 months
for stage IV patients (n= 36), irrespective of treatment.
When first treatment was considered (n= 35), mOS for
stage IV patients was 8.9, 16.6, 21.7, and 3.7 months, for
patients who had received chemotherapy (ChT) (n= 17),
immunotherapy (n= 9), targeted therapy (TT) (n= 3), and no
therapy (n= 6), respectively. The overall response rate was
44% (7/16 patients) to ChT, 100% to TT (3/3), and 25% to
ipilimumab (2/8). In our study, Breslow thickness
represents the best prognostic factor for OS. In stage IV
ALM patients treated with either immunotherapy or TT, there
is a trend for extended mOS compared with ChT. Melanoma
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Introduction
Acral lentiginous melanoma (ALM) is a unique subtype
of melanoma that affects the glabrous skin of the palms
and soles, including the nail apparatus [1,2].
Histologically, it shows a proliferation of atypical mela-
nocytes along the dermoepidermal junction, extending
into deeper structures in cases of invasive disease.
ALM is rare in the White population and accounts for
1–3% of all melanomas in Switzerland [2]; however, it is
the most common melanoma subtype found in dark-
skinned and Asian populations [3]. In contrast to cuta-
neous melanomas (CM), ultraviolet (UV) radiation does
not seem to play a major pathogenetic role in ALM [4];
however, some groups considered mechanical stress to
be one of the main factors that increase the formation
of melanomas on the plantar surface and pressure points
[5,6]. There seem to be distinct patterns of genetic
alterations within melanoma subtypes, including different
chromosomal aberrations and frequency of mutations of
specific genes, suggesting that distinct tumor subtypes
develop through different molecular pathways. One of the
characteristics of ALM is its unique genomic instability,
which results in numerous focused gene amplifications and
deletions, which can already be detected at early stages of
the disease [1,4]. Activating BRAF and NRAS mutations
are the most common genetic aberrations in cutaneous
melanoma, but are detected only in 13–20% [7,8] and
12–25% [8,9] of ALMs, respectively. In contrast, although
rare in CM (1.7–14%) [10,11], KIT has been reported to be
the most commonly mutated gene in ALM, affecting
5–36% of tumors [1,11]. Determination of the genetic
background has implications for melanoma therapy as KIT
mutated tumors show response to therapy with tyrosine
kinase inhibitors Nilotinib [12] and Imatinib [11].
Because of the low incidence of ALM in the White
population, only a few studies on this melanoma subtype
exist to date [13–16]. Despite its rarity, it is an especially
important subtype as it seems to lead to a poorer prognosis
compared with CM [17,18].
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We present one of the largest cohorts of ALM from a single
referral center in Switzerland. The aim of our study was to
analyze the clinicopathological characteristics, prognostic
factors, response to systemic therapy, and overall survival
(OS) of patients with ALM.
Patients and methods
Patient selection and data acquisition
We carried out a single-center retrospective cohort study of all
patients who had been diagnosed and/or treated for ALM at
the Department of Dermatology of the University Hospital
Zurich, Switzerland, from January 2005 to December 2015.
Patients were selected from our DermaPro database system
(ifms GmbH, Saarbrücken, Germany) using the keywords
‘acral, acral lentiginous, ALM’. Demographic and clinical
information was obtained from electronic medical records;
missing information was collected through phone interviews
with the attending dermatologist or the patient himself/
herself.
The primary tumor specimens were retrieved and sub-
jected to re-examination by an experienced dermato-
pathologist (R.D. or D.K.). The diagnosis of ALM,
location (ALM of palmoplantar glabrous skin vs. ALM of
nail apparatus), and tumor characteristics such as Breslow
thickness and ulceration status were re-evaluated. If the
primary excision was performed in an external pathology
institute, the slides were ordered for re-evaluation. Only
patients with available primary tumor specimens and
with a histologically confirmed melanoma arising from
the glabrous skin of palmoplantar areas or from the nail
apparatus were included in the study.
The demographical and clinicopathological parameters of
eligible patients, including age, sex, mutational status,
and primary tumor characteristics, were obtained.
The electronic medical records were also reviewed for status
of sentinel lymph node biopsy (SLNB) and data on the
metastatic pattern. Lymphatic route was defined as devel-
oping metastases first confined to the drainage area of
regional lymph nodes (corresponding to satellite/in-transit
metastases, micrometastases in the SLNB, or clinically
recognizable macrometastases in regional lymph nodes),
followed by the development of distant metastases [19].
Hematogenous spread was defined as developing distant
organ metastases, without previous metastatic involvement
of regional lymph nodes. Stage IV patients were divided into
four groups according to the first treatment received: che-
motherapy (ChT), immunotherapy (IT), targeted therapy
(TT), and no systemic therapy.
OS of the entire cohort was calculated from the date of first
diagnosis until the date of death or last follow-up. OS of
metastatic patients was calculated from the date of first distant
metastasis until the date of death or last follow-up.
Progression-free survival (PFS) was calculated from treatment
initiation until progression or last follow-up. The overall
response rate (ORR) was defined as the proportion of patients
who showed a partial or a complete response to therapy at the
3-month follow-up by PET-CT.
Informed consent for tissue storage including a retro-
spective analysis with collection of clinical, laboratory,
and histological information was approved by the local
ethics committee (KEK-ZH-Nr. 647, 800) and signed by
the study participants.
Statistical analysis
Survival analysis was carried out using the log-rank test.
Relevant clinical parameters (age, Breslow thickness, sex,
etc.) were evaluated by univariate and multivariate Cox
regression. The χ2-test was used to compare the clinical
factors between the nonmetastatic and metastatic ALM
patients. A P value of less than 0.05 was considered sta-
tistically significant.
Results
Patient characteristics
A total of 172 patients fulfilled the inclusion criteria and
were included for analysis (Supplementary Fig., Supplemental
digital content 1, http://links.lww.com/MR/A43, for a schematic
display of the patient selection process). For clinical and his-
tological images of ALMs of our series, see Fig. 1. Of all the
patients, 96 (55.8%) were women and 76 (44.2%) were men.
The median age at first diagnosis was 65 years (range:
27–93 years). The demographical and clinicopathological
characteristics of the patients are presented in Table 1. The
tumor originated from the glabrous skin of palms and soles in
109 (63.4%) cases and from the nail apparatus in 59 (34.3%)
cases. In four cases, the pathologist could not distinguish
between glabrous skin and the nail apparatus. Ulceration was
present in 53 (42.7%) cases. There were nine (36%) of 25
patients with the NRAS mutation, five (23.8%) of 21 patients
with the KITmutation, and six (16.2%) of 37 patients with the
BRAF mutation. Mutation analysis was not carried out in all
patients. Most of the tumors were located on the lower
extremities [130/172 (75.6%)]. The heel was the most com-
mon location [36/130 (27.7%)], followed by a subungual
location [26/130 (20%)], forefoot, and midfoot [22/130 (16.9%)
each]. Of the tumors occurring on the upper extremities,
three-quarters [32/42 (76.2%)] were subungual. For a gra-
phical representation of tumor location, see Fig. 2 (see
Supplementary Table, Supplemental digital content 2,
http://links.lww.com/MR/A44, which shows details on the
location of melanomas).
SLNB was performed in 90 of 154 patients with patho-
logic stage of at least pT1 [90/154 (58.4%)] and was
positive in 28 (30.1%) of these patients (Table 1).
Metastatic spread
At first diagnosis, a quarter of the patients with pathologic
stage of at least pT1 [36/154 (23.4%)] had metastatic
ALM, three of whom had distant organ metastases
[AJCC stage IV, 3/36 (8.3%)]. However, by the time of
Metastatic ALM in Switzerland Häfliger et al. 443
the last follow-up, the percentage of metastatic disease
had increased to 43.5% (67/154). Of the patients with
metastatic ALM at the last follow-up, 40 had distant
organ metastases: of the 40 patients, 30 (75%) presented
with pulmonary metastases, 25 (62.5%) presented with
hepatic metastases, 22 (55%) presented with bone
metastases, 18 (45%) presented with metastases in other
visceral organs, and 12 (30%) presented with cerebral
metastases.
Sixty-three (94%) of 67 patients showed a melanoma
metastasizing by the lymphatic route, whereas only one
(1.5%) of the 67 patients showed hematogenous spread.
In three cases, the metastatic route could not be assessed
because no SLNB was performed and patients showed
distant organ metastases as the first manifestation of
metastatic disease. Details of the metastatic pattern are
shown in Table 2.
Treatment characteristics
A total of 35 stage IV patients were analyzed according to
the first systemic treatment. Seventeen patients received
ChT, nine patients received IT, three patients received
Fig. 1
Clinical and histological images of five acral lentiginous melanomas (ALMs) of our series. Images (c) and (f) are from the same patient. The rest of the
images each stems from a different patient. (a) A nonulcerated ALM of the heel with Breslow 0.7 mm. A lentiginous growth pattern, in which the
melanocytes are arranged as solitary units along the basilar epidermis, and the typical propensity of ALM to involve sweat glands can be seen. The
thick stratum corneum is a characteristic of plantar location. (b) An ulcerated ALM with Breslow 10 mm of the forefoot. (c, f) An ulcerated subungual
melanoma of the hallux with Breslow 3.5 mm. (d) An ALM occurring on the heel. (e) An ALM located on the forefoot.
444 Melanoma Research 2018, Vol 28 No 5
TT, and six patients did not receive any systemic therapy
(Table 3). One patient was excluded from this analysis
because he was treated with dacarbazine/adeno-inter-
leukin-2 as the first therapy.
Four (24%) of 17 patients received ChT as the first-line
and second-line treatment, whereas for eight (47%) of 17
patients, the therapy was switched to IT or TT. Out of 22
patients, who received IT or TT as the first systemic
therapy, eight (27%) were switched to another IT or TT as
the second-line treatment, whereas eight (27%) patients
were switched to ChT. Overall, 13 patients received more
than two systemic treatments. (see Supplementary Table,
Supplemental digital content 3, http://links.lww.com/MR/
A45, for details on systemic therapy).
ORR was 44% for ChT (7/16), 100% for TT (3/3), and 22%
for any IT (2/9) (Table 3). Eight of the nine patients treated
with IT received ipilimumab. ORR to ipilimumab first-line
treatment in our cohort was 25% (2/8) (see Supplementary
Table, Supplemental digital content 4, http://links.lww.com/
MR/A46, for details of response to first systemic therapy).
Survival data
By the time of the last data collection in September 2016, 108
(62.8%) patients were still alive, 51 (29.7%) patients had died,
and 13 patients were lost to follow-up. The median follow-up
duration was 49 months (range: 0.1–260.1 months).
Table 1 Patient demographical and clinicopathological
characteristics
Nonmetastatic
(n=105) [n (%)]
Metastatica (n=67)
[n (%)]
Sex
Male 42 (40) 34 (50.8)
Female 63 (60) 33 (49.3)
Age (years) 65 (29–86) 65 (27–93)
Origin
Glabrous skin 62 (59) 47 (70.1)
Nail apparatus 43 (41) 16 (23.9)
Unknown 0 (0) 4 (6)
Location
Lower extremities 77 (73.3) 53 (79.1)
Upper extremities 28 (26.7) 14 (20.9)
Breslow (mm) 1.8 (0.2–15) 4.2 (0.5–15)
Breslow index (mm) [20]
In situ 18 (17.1) 0 (0)
0.1–1.0 33 (31.4) 5 (7.5)
1.01–2.0 27 (25.7) 7 (10.5)
2.01–4.0 22 (21) 27 (40.3)
>4.0 4 (3.8) 25 (37.3)
Unknown 1 (1) 3 (4.5)
Ulceration
Yes 20 (19.1) 33 (49.3)
No 45 (42.9) 26 (38.8)
Unknown 22 (21) 8 (11.9)
Not applicable 18 (17.1) 0 (0)
Stage at first diagnosis [20]
I 63 (60) 4 (6)
II 37 (35.2) 24 (35.8)
III 0 (0) 33 (49.3)
IV 0 (0) 3 (4.5)
Unknown (stage I or II) 5 (4.8) 3 (4.5)
Mutational status
BRAF status
Mutated
(V600E, D594N)
0 (0) 6 (9)
Wild type 0 (0) 31 (46.3)
Unknown 105 (100) 30 (44.8)
NRAS status
Mutated
(G12, G13, Q61)
0 (0) 9 (13.4)
Wild type 0 (0) 16 (23.9)
Unknown 105 (100) 42 (62.7)
KIT status
Mutated (Exon 9, 11,
13, 17, 18)
0 (0) 5 (7.5)
Wild type 0 (0) 16 (23.9)
Unknown 105 (100) 46 (68.7)
SLNB
T1–T4 (n=154)b
Positive 0 (0) 28 (41.8)
Negative 47 (54.0) 15 (22.4)
Not performed 40 (46.0) 24 (35.8)
Age is reported in years as median age and range.
Breslow thickness is reported in mm as mean Breslow and range. All other
variables are reported in n (%).
aAt the time of the last follow-up.
bPatients with melanoma in situ were excluded.
Fig. 2
Graphical representation of tumor location. (a–b) Percentages refer to the
total of melanomas of the lower extremities. The total is not 100%, because
the exact location of 8.5% of tumors is unknown. (c–d) Percentages refer
to the total of melanomas of the upper extremities.
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The median OS (mOS) was 155.7 months in the entire
cohort and 11.2 months for stage IV patients, irrespective
of treatment (Fig. 3a and b).
The 5-year OS was 45.2% (14/31) for stage III patients
and 5.6% (2/36) for stage IV patients (Fig. 3b). The
5-year OS for stage I–II patients could not be calculated,
mainly because of the very short follow-up period.
The median PFS for the first treatment was 2.1 months
for ChT (n= 17), 2.1 months for IT (n= 9), and
11.4 months for TT (n= 3) (Table 3 and Fig. 3c). When
the first treatment was considered, mOS for stage IV
patients was 8.9, 16.6, 21.7, and 3.7 months, for patients
who received ChT, IT, TT, and no therapy (n= 6),
respectively (Table 3 and Fig. 3d). We compared mOS of
ChT versus IT and of ChT versus TT and observed a
trend toward longer mOS in stage IV ALM patients
treated with either IT or TT compared with ChT
(P= 0.057 for ChT vs. IT, P= 0.056 for ChT vs. TT).
Prognostic factors for overall survival
In univariate Cox regression, Breslow thickness
(P< 0.001), age (P= 0.003), status of sentinel lymph node
(P= 0.005), and ulceration (P= 0.008) were identified as
significant prognostic factors for OS in ALM (Fig. 3e).
However, only Breslow thickness was a significant
prognostic factor for OS (P= 0.0003) in multivariate Cox
regression. Sex (P= 0.431) failed to show statistical sig-
nificance in both univariate and multivariate Cox
regression (Fig. 3f).
Prognostic factors for metastatic disease
Patients with metastatic disease at the time of the last
follow-up were more likely to have had ulceration
(P= 0.008) and pathologic stage of more than pT2
(P< 0.0001) at first diagnosis. Almost 15 (25%) of the 65
patients with negative SLNB developed metastatic dis-
ease. Subdivided by pathologic tumor stage, five of six
patients with pT4 and nine of 27 patients with pT3
eventually developed metastatic disease, despite the
negative SLNB, whereas only one of 10 patients with
pT1 and none of the pT0–T2 patients with negative
SLNB developed metastases (see Supplementary Table,
Supplemental digital content 5, http://links.lww.com/MR/
A47, for details on patients in whom SLNB was per-
formed) (see Supplementary Fig., Supplemental digital
content 6, http://links.lww.com/MR/A48, for OS according
to the status of sentinel lymph node).
Table 2 Clinical course and metastatic pattern of 67 patients
Stage (AJCC) [20] n (%) (N=67) Location of metastases n (N=40) Number of affected organs n (N=40)
At the time of first diagnosis
I 4 (6) Lung 3 1 organ 3
II 24 (35.8) Lung, liver, bone, adrenal 1 2–3 different organs 0
III 33 (49.3) ≥4 different organs 1
IV 3 (4.5)
Unknown 3 (4.5)
At time of the last follow-up
III 26 (38.8) Lung 30 (75) 1 organ 8 (20)
IV 41 (61.2) Liver 25 (62.5) 2–3 different organs 18 (45)
M1a 1 (2.4) Bone 22 (55) ≥4 different organs 14 (35)
M1b or M1c 40 (97.6) Brain 12 (30)
Other viscerala 18 (45)
Route of metastasizing
Lymphatic 63 (94)
Only lymph nodes 30 (47.6)
Lymph nodes and satelliteb 28 (44.4)
Only satelliteb 5 (7.9)
Hematogenous 1 (1.5)
Unknown 3 (4.5)
Variables are reported in n (%). N=67 represents the total of patients with metastatic disease at the time of last follow-up. N=40 represents the total of patients with
distant organ metastases at the time of last follow-up.
aAdrenal gland, kidney, spleen, pancreas, gallbladder, urinary blatter, intestine, peritoneal carcinomatosis, stomach, heart, thyroid gland, and palatine tonsil.
bSatellite or in-transit metastases.
Table 3 Characteristics of the first systemic treatment, overall
response rate, median PFS, and median OS
Stage IV
[20]a ORR (%)
Median PFS
(months)
Median OS
(months)
First systemic treatment (n=35)
ChT 17 (48.6) 44 2.1 8.9
IT 9 (25.7) 22 2.1 16.6
TT 3 (8.6) 100 11.4 21.7
None 6 (17.1) – – 3.7
Ipilimumab as the
first-line treatment
(n=8)
– 25 2.1 21
Variables are reported in n (%).
Chemotherapy included dacarbazine, temozolamide, avastin, vinorelbine +
cisplatin (VP), taxol, and depocyte. Immunotherapy included ipilimumab, pem-
brolizumab and one patient with tremelimumab.
Targeted therapy included BRAF-inhibitors (vemurafenib), MEK-inhibitors (trame-
tinib, selumetinib), BRAF/MEK-inhibitors (dabrafenib + trametinib), multikinase
inhibitors (imatinib, sorafenib), and tyrosine kinase inhibitors (nilotinib, pazopanib).
For analysis of the first systemic treatment, 1 patient was excluded because he
had received dacarbazine/adeno-IL-2 as the first treatment.
ChT, chemotherapy; IT, immunotherapy; ORR, overall response rate; OS, overall
survival; PFS, progression-free survival; TT, targeted therapy.
aStage refers to beginning of systemic therapy.
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Discussion
We report a large series of 172 patients with ALM from a
single tertiary referral center in Switzerland. In this study,
we focus on the clinicopathological characteristics, prog-
nostic factors, response to systemic therapy, and OS of
this cohort.
Fig. 3
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(a) Overall survival (OS) of the entire cohort (n=172) from the date of first diagnosis until death or the last follow-up. (b) OS for stage III patients
(n=31) versus stage IV patients (n=36). OS of metastatic patients was calculated from the date of first distant metastasis until death or the last
follow-up. The 5-year OS was 45.2% (14/31) for stage III and 5.6% (2/36) for stage IV patients. (c) Progression-free survival (PFS) for stage IV
patients according to the first received treatment (n=35): chemotherapy (n=17) versus immunotherapy (n=9) versus targeted therapy (n=3)
versus no systemic therapy (n=6). PFS was calculated from treatment initiation until progression or the last follow-up. (d) OS for stage IV patients
according to the first received systemic treatment (n=35): chemotherapy (n=17) versus immunotherapy (n=9) versus targeted therapy (n=3)
versus no systemic therapy (n=6). OS was calculated from the date of first distant metastasis until death or the last follow-up. (e) In univariate Cox
regression, Breslow thickness, age, status of sentinel lymph node, and ulceration were identified as significant prognostic factors for OS in acral
lentiginous melanoma (ALM). (f) In multivariate analysis, only Breslow thickness showed statistical significance. A P value of less than 0.05 was
considered as statistically significant. Crosses indicate censored patients. NA, not applicable because 50% death was not reached; OS, overall
survival; PFS, progression free survival.
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The characteristics of the patient population, examined
in this study, are in good agreement with those reported
in similar studies. Most tumors occurred in female
patients [16,17], and the mean age at first diagnosis was
64.4 years, which is only slightly higher than previously
published data, reporting a mean age ranging from 55 to
63 years [16–18].
Recent studies in the Asian population found a higher
incidence of ALM at more physically stressed sites such
as the heels [5,21], whereas formation of ALM in the arch
of the foot was reported to occur more commonly in
obese patients [6], known to experience flattening of the
foot and formation of new pressure points. These
observations, along with our data of White patients,
suggest that mechanical stress plays a major pathogenetic
role in plantar melanoma; however, a more detailed
analysis is needed.
Since the Food and Drug Administration approval of TT
with kinase inhibitors and IT with immune checkpoint
inhibitors in 2011, genetic testing for potential driver
mutations with the prospect of treatments became
important. In our cohort, the most frequent mutations
were found in NRAS, followed by KIT and BRAF genes.
The percentage of KIT mutations of our study is
in accordance with the data provided by other authors
[1,11]; however, we found a relatively high percentage of
NRAS mutations. This could be because of missing data
as a considerable proportion of our patient cohort had
been diagnosed and/or treated before the introduction of
routine screening for individual mutational profiles.
In the past decade, the role of SLNB as an important
prognostic factor for recurrence and OS in CM has been
proven. It is nowadays a standard procedure for patients
with CM with a Breslow thickness of at least 1.0 mm or at
least 0.8 with ulceration and clinically nonpalpable
regional lymph nodes [2,22]. However, in noncutaneous
melanoma, the value of SLNB remains controversial
[23,24]. The literature on the relevance of SLNB in ALM
is limited to small cohort studies; however, positive
SLNB was identified as the main predictor for recurrence
and worse survival in a cohort of 85 ALM patients [15],
and in another study, ALM patients with positive SLNB
were reported to have a significantly worse 5-year OS
(37.5 vs. 84.3%) and 5-year PFS (37.5 vs. 77.9%) com-
pared with patients with negative SLNB [25]. We found
positive SLNB to be a prognostic factor for lower OS in
univariate Cox analysis; however, almost 25% of the
patients with negative SLNB developed metastatic dis-
ease. The false-negative predictive value of SLNB for
our ALM series is higher than that reported for CM
(11–16%) [26,27]. This may in part be explained by the
fact that our dataset was incomplete. In fact, SLNB was
only performed in 58.4% of patients. Also, most of our
SLNBs were not performed at a specialized center; thus, the
high quality of histopathological assessment of SLNB [28]
might not always have been provided.
Distinct melanoma subtypes show different metastatic
patterns [28], with ALM and mucosal melanoma showing
a tendency to develop significantly more bone metastases
compared with other melanomas. In our cohort of meta-
static ALM, bone metastases were found in over a half of
the patients. It has been reported that the cytokine tumor
growth factor-β plays an important role in antagonizing
the development of bone metastases in melanoma and
breast cancer [29,30]. Thus, the differences in organ
preferences of metastatic spread within distinct melan-
oma subtypes might derive in part from a different
dependence on tumor growth factor-β signaling path-
ways [28].
Until 2011, ChT with dacarbazine was considered the
standard treatment for patients with inoperable or meta-
static melanoma and alternatives were limited [31]. It
yielded objective response rates of 5–15% in several
phase III studies, but failed to show an impact on OS, so
that until 2011, the median OS was only 8–10 months
with approved therapies for stage IV melanoma [31–35].
In our study, ChT as the first-line treatment showed an
ORR of 44% for stage IV ALM, which is higher than
previously reported data for CM. However, the mOS of
8.9 months was within the range reported in the literature
for CM [32–35]. Fortunately, treatment of metastatic
melanoma has changed considerably over the last decade
with the development of IT and TT. These new drugs
not only show better ORR compared with ChT but also
improve OS [36]. Ipilimumab, which blocks cytotoxic
T-lymphocyte-associated antigen 4 to augment antitumor
T-cell immunity, was the first agent to show a benefit for
OS in metastatic melanoma in randomized-controlled
phase III trials [19,37,38].
The mOS of patients treated with ipilimumab in our
cohort was almost twice as long (21 months) as the
reported median OS for patients with CM (11.4 months)
[39]. Although the response rate to ipilimumab is only
15% in CM, up to 21% of stage IV patients, independent
of previous therapy, achieve remarkable durable remis-
sion [19,39]. In our study, two (25%) of eight patients
responded to ipilimumab as the first systemic treatment,
and one of them showed a durable remission of
37.2 months. Until the time of data collection, this
patient did not receive other systemic treatments after
ipilimumab and did not show any tumor progression. The
considerable difference in the mOS and ORR between
our data and the literature might be because of the small
number of patients who received ipilimumab as the first
treatment in our study (n=8). As the clinical outcome of
stage IV melanoma patients treated with ipilimumab is
not reported separately for the ALM subcategory in the
literature, but exclusively for stage IV melanoma patients
overall, without differentiation of histological subtype,
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this difference could also be explained by different sus-
ceptibilities of the various melanoma subtypes to ipili-
mumab. In our study, we found a trend toward extended
mOS in stage IV ALM patients treated with either IT or
TT compared with ChT. The lack of statistical sig-
nificance is likely because of the low number of patients
whom we included in treatment analysis.
Teramoto et al. [16] analyzed a cohort of 2050 ALMs and
suggested that advanced age, ulceration, tumor thickness,
and tumor spread at first diagnosis were reliable indepen-
dent prognostic factors for disease-specific survival, and
hence, the present AJCC classification for CM can be
considered valid for ALM. In our study, we found Breslow
thickness, age, status of sentinel lymph node, and ulcera-
tion to be prognostic factors for OS in univariate analysis.
The finding of SLNB as a prognostic factor for OS is in line
with previously published data [15,25].
ALM seems to be associated with worse prognosis com-
pared with CM. In patients with stage III disease, the
5-year OS was reported to be 61.2 versus 66.1% for ALM
and CM, respectively [18]. As for stage IV patients, the
5-year OS was 22.2 versus 25.5%, respectively, for ALM
and CM [18]. In our study, the 5-year OS was 45.2% for
stage III patients and 5.6% for stage IV patients.
The reasons for the unfavorable prognosis of ALM remain
unclear. Because of the hidden location of plantar melanomas
and the striking similarity of subungual tumors to hematomas,
ALM is often diagnosed in a more advanced tumor stage
compared with CM [17–19]. Besides the delayed diagnosis,
the lower survival rates found in ALMmay also be caused by
a different biological tumor behavior [4,11,13,16,18,40,41].
Newly reported prognostic genetic biomarkers in ALM may
contribute toward a better prognostication of ALM patients.
Amplification of the telomerase reverse transcriptase (TERT)
gene, and increased levels of β-catenin, lymphoid enhancer-
binding protein-1, and heparanase-1 were reported to be
associated with poor outcomes in ALM [42,43].
The retrospective setting, the small cohort of metastatic
patients, and the diversity of systemic therapies adminis-
tered to these patients are clear limitations of our study.
To our knowledge, this is the largest study reporting the
exact location of ALM.
Conclusion
ALM is a unique subtype of melanoma, which is char-
acterized by a poorer prognosis compared with CM. As
delayed diagnosis seems to be one of the main causes for
poor outcomes in ALM, sensitization of the population to
the existence of melanoma on hidden locations such as
acral sites or the nail apparatus, and regular skin checks
and self-examinations of acral sites may lead to earlier
diagnosis and therefore directly improve survival.
Moreover, we found a trend toward extended mOS in
stage IV ALM patients treated with either IT or TT
compared with ChT. Prospective clinical trials with larger
cohorts of stage IV ALM patients are needed to further
elucidate the effect of new systemic therapies such as IT
and TT on the survival of ALM patients.
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